Table 2.
Bioavailability of rosiglitazone and N-desmethylrosiglitazone co-administered with febuxostat relative to rosiglitazone co-administered with placebo
| Parameter | Point estimate | 90% Confidence interval |
|---|---|---|
| Rosiglitazone; regimen A vs. regimen B | ||
| C max | 0.9447 | 0.8924–0.9999 |
| AUC0–tlqc | 1.0209 | 1.0024–1.0398 |
| AUC0–∞ | 1.0219 | 1.0032–1.0410 |
| N-Desmethylrosiglitazone; regimen A vs. regimen B | ||
| C max | 0.9882 | 0.9687–1.0081 |
| AUC0–tlqc | 1.0010 | 0.9829–1.0194 |
| AUC0–∞ | 1.0005 | 0.9836–1.0177 |
| Metabolite-to-parent ratios | ||
| C max ratio | 1.0461 | 0.9888–1.1067 |
| AUC0–tlqc ratio | 0.9805 | 0.9635–0.9977 |
| AUC0–∞ ratio | 0.9790 | 0.9627–0.9957 |
Abbreviations: Cmax, maximal plasma concentration; AUC0–tlqc, area under the curve from time 0 to the time of last quantifiable concentration; AUC0–∞, area under the curve from time 0 to infinity.